Clinical TrialsThe initiation of the new Phase 2b trial is seen as a major milestone for Arbutus, reinforcing the positive outlook for the company's future developments.

Financial StabilityManagement estimates its cash holdings to sufficiently fund its operations through the first quarter of 2028, allowing for the full funding of the upcoming imdusiran Phase 2b trial.

Therapeutic DevelopmentsAnalyst recommends a Buy rating, affirming confidence in the potential of imdusiran as a core component for achieving a functional cure in HBV.

Bears Say

Discontinued TrialsArbutus has discontinued the planned IM-PROVE III Phase 2a trial of imdusiran plus anti-PD-L1 antibody durvalumab prior to initiation.

Legal ProceedingsArbutus and partner Genevant expand their LNP legal activity against Moderna globally, with ongoing suits around LNP patents.

Restructuring CostsArbutus anticipates a one-time restructuring charge of ~$11M-$13M in 1Q25.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

1.17% Insiders

10.56% Mutual Funds

22.86% Other Institutional Investors

55.80% Public Companies and Individual Investors

Detailed Ownership Overview >

ABUS FAQ

What was Arbutus Biopharma Corporation’s price range in the past 12 months?

Arbutus Biopharma Corporation lowest stock price was $2.71 and its highest was $4.72 in the past 12 months.

What is Arbutus Biopharma Corporation’s market cap?

Arbutus Biopharma Corporation’s market cap is $599.48M.

When is Arbutus Biopharma Corporation’s upcoming earnings report date?

Arbutus Biopharma Corporation’s upcoming earnings report date is Jul 31, 2025 which is in 29 days.

How were Arbutus Biopharma Corporation’s earnings last quarter?

Arbutus Biopharma Corporation released its earnings results on May 14, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.104 by -$0.026.

Is Arbutus Biopharma Corporation overvalued?

According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arbutus Biopharma Corporation pay dividends?

Arbutus Biopharma Corporation does not currently pay dividends.

What is Arbutus Biopharma Corporation’s EPS estimate?

Arbutus Biopharma Corporation’s EPS estimate is -0.04.

How many shares outstanding does Arbutus Biopharma Corporation have?

Arbutus Biopharma Corporation has 191,527,130 shares outstanding.

What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?

Arbutus Biopharma Corporation reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.104. Following the earnings report the stock price went down -0.94%.

Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?

Currently, no hedge funds are holding shares in ABUS

Arbutus Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-79.02%

Trailing 12-Months

Asset Growth

-22.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.